Percutaneous transcatheter aspiration of pulmonary embolism leading to diagnosis of hepatocellular carcinoma tumor embolus and change in systemic chemotherapy
Abstract: The management of metastatic hepatocellular carcinoma (HCC) is complex, particularly when complicated by pulmonary embolism. In these cases, atezolizumab-bevacizumab therapy is contraindicated due to an elevated risk of thromboembolic events. Differentiating pulmonary tumor embolism from thromboembolic disease is diagnostically challenging. This report outlines the benefit of transcatheter aspiration to obtain pathological evidence of pulmonary artery tumor embolus in an HCC patient. The intervention enabled a significant shift in the management strategy, leading to an escalation of systemic HCC therapy. This case underscores the importance of precise diagnostic techniques such as transcatheter aspiration in guiding treatment decisions, particularly in cases where pulmonary embolism may signify an underlying malignancy-driven process
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Acta radiologica open. - 13, 6 (2024) , 1-5, ISSN: 2058-4601
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2024
- Urheber
-
Verloh, Niklas
Vogt, Katharina
Bettinger, Dominik
Schultheiß, Michael
Kandilaris, Kosmas
Holzner, Philipp Anton
Doppler, Michael
Uller, Wibke
- DOI
-
10.1177/20584601241253780
- URN
-
urn:nbn:de:bsz:25-freidok-2491167
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Verloh, Niklas
- Vogt, Katharina
- Bettinger, Dominik
- Schultheiß, Michael
- Kandilaris, Kosmas
- Holzner, Philipp Anton
- Doppler, Michael
- Uller, Wibke
- Universität
Entstanden
- 2024
Ähnliche Objekte (12)
HCC-Biomarker in der Diagnostik und Therapie des Hepatozellulären Karzinoms (HCC) in verschiedenen Phasen der Erkrankung
Klinisches Vorgehen bei Leberabszessen
Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma : : a response‐based approach
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
Evaluation einer Definition und der Prävalenz des hyperdynamischen Kreislaufes bei Patienten mit Leberzirrhose und Aszites
Routine colonoscopy in patients with high risk of non-occlusive mesenteric ischemia
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC : : an international observational study
HCC-Biomarker in der Diagnostik und Therapie des Hepatozellulären Karzinoms (HCC) in verschiedenen Phasen der Erkrankung
Klinisches Vorgehen bei Leberabszessen
Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma : : a response‐based approach
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
Evaluation einer Definition und der Prävalenz des hyperdynamischen Kreislaufes bei Patienten mit Leberzirrhose und Aszites
Routine colonoscopy in patients with high risk of non-occlusive mesenteric ischemia
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC : : an international observational study
HCC-Biomarker in der Diagnostik und Therapie des Hepatozellulären Karzinoms (HCC) in verschiedenen Phasen der Erkrankung
Klinisches Vorgehen bei Leberabszessen
Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma : : a response‐based approach
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
Evaluation einer Definition und der Prävalenz des hyperdynamischen Kreislaufes bei Patienten mit Leberzirrhose und Aszites
Routine colonoscopy in patients with high risk of non-occlusive mesenteric ischemia
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma